drugset
drugset / Trial / NCT02802735

Study to Evaluate the Pharmacokinetics of Single and Multiple Doses of Apremilast in Healthy Adult Male Korean Subjects

NCT02802735 ↗

Phase 1 Completed 28 enrolled Amgen
RandomizedCrossoverOpen-labelTreatment

Summary

This two-part study was designed to evaluate the pharmacokinetics (PK) of single and multiple doses of apremilast in healthy adult Korean males.

Timeline

Start
2016-06-22
Primary completion
2016-08-05
Completion
2016-08-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Apremilast Small molecule 20 mg Oral
Subject Apremilast Small molecule 30 mg Oral
Subject Apremilast Small molecule 40 mg Oral

Indications

No indication recorded.